"Quetiapine Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
| Descriptor ID |
D000069348
|
| MeSH Number(s) |
D02.886.680.702.500.500 D03.633.300.276.500
|
| Concept/Terms |
Quetiapine Fumarate- Quetiapine Fumarate
- Fumarate, Quetiapine
- Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt)
ICI 204,636- ICI 204,636
- 204,636, ICI
- ICI-204636
- ICI204636
- ICI 204636
- 204636, ICI
Quetiapine- Quetiapine
- 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
|
Below are MeSH descriptors whose meaning is more general than "Quetiapine Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Quetiapine Fumarate".
This graph shows the total number of publications written about "Quetiapine Fumarate" by people in this website by year, and whether "Quetiapine Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quetiapine Fumarate" by people in Profiles.
-
Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275.
-
Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder. Ann Pharmacother. 2018 09; 52(9):838-848.
-
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry. 2015 Oct; 60(10):441-50.
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
-
Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014 Jun; 34(3):359-64.
-
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Res. 2012 Dec 30; 200(2-3):126-32.
-
Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012 Apr; 10(2):83-94.
-
Charles Bonnet syndrome as a manifestation of leptomeningeal metastases. Psychosomatics. 2010 Sep-Oct; 51(5):447.
-
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008 Mar; 24(3):709-16.
-
Quetiapine for mania due to traumatic brain injury. CNS Spectr. 2007 Oct; 12(10):764-9.